LU90866I2 - Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine - Google Patents

Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine

Info

Publication number
LU90866I2
LU90866I2 LU90866C LU90866C LU90866I2 LU 90866 I2 LU90866 I2 LU 90866I2 LU 90866 C LU90866 C LU 90866C LU 90866 C LU90866 C LU 90866C LU 90866 I2 LU90866 I2 LU 90866I2
Authority
LU
Luxembourg
Prior art keywords
sibutramine hydrochloride
derivatives
pharmaceutically acceptable
acceptable salts
monohydrate
Prior art date
Application number
LU90866C
Other languages
English (en)
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23060006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90866(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of LU90866I2 publication Critical patent/LU90866I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU90866C 1988-11-29 2001-12-18 Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine LU90866I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27724088A 1988-11-29 1988-11-29

Publications (1)

Publication Number Publication Date
LU90866I2 true LU90866I2 (fr) 2002-02-18

Family

ID=23060006

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90866C LU90866I2 (fr) 1988-11-29 2001-12-18 Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine

Country Status (15)

Country Link
US (1) US5436272A (fr)
EP (1) EP0397831B1 (fr)
JP (1) JPH06102622B2 (fr)
KR (1) KR0164435B1 (fr)
AU (1) AU633529B2 (fr)
CA (1) CA2003524C (fr)
DE (2) DE19975039I2 (fr)
DK (1) DK175587B1 (fr)
IE (1) IE61928B1 (fr)
IL (1) IL92406A (fr)
LU (1) LU90866I2 (fr)
NL (1) NL300066I2 (fr)
PH (1) PH26677A (fr)
WO (1) WO1990006110A1 (fr)
ZA (1) ZA899058B (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
AU721924B2 (en) * 1992-06-23 2000-07-20 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
MXPA01009464A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Metodo para el tratamiento de apnea de sueno.
WO2000056306A1 (fr) * 1999-03-19 2000-09-28 Knoll Gmbh Traitement de l'arthrose
US6372798B1 (en) 1999-03-19 2002-04-16 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
NZ514015A (en) * 1999-03-19 2001-09-28 Knoll Gmbh Weight loss after pregnancy
WO2000056310A1 (fr) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Traitement du syndrome de fatigue chronique
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
CA2367666C (fr) * 1999-03-19 2008-11-25 Carl M. Mendel Traitement des troubles de l'alimentation
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
BR0009159A (pt) * 1999-03-19 2001-12-26 Knoll Gmbh Método de controle do ganho de peso associadocom drogas terapêuticas
US6433020B1 (en) 1999-03-19 2002-08-13 Knoll Pharmaceutical Company Treatment of cardiovascular disease
MXPA01009468A (es) 1999-03-19 2004-03-19 Knoll Gmbh Tratamiento de hipertension pulmonar.
AU4014800A (en) * 1999-03-19 2000-10-09 Knoll Gmbh Treatment of gallstones
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9926251D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Pharmaceutical formulation
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
WO2002019998A2 (fr) * 2000-09-08 2002-03-14 Eli Lilly And Company Traitement des prises de poids associees a l'utilisation d'antipsychotiques atypiques
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
JP3813152B2 (ja) * 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
WO2005028438A1 (fr) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
EP1734963A4 (fr) 2004-04-02 2008-06-18 Merck & Co Inc Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques
KR100830002B1 (ko) 2005-01-06 2008-05-15 씨제이제일제당 (주) 시부트라민의 무기산염
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
EP1916239A4 (fr) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd Composé de pyridone
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
JPWO2007034910A1 (ja) * 2005-09-22 2009-03-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 過食症及び過食症に伴ううつ病の治療用医薬組成物
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
EP1944301A4 (fr) 2005-10-27 2012-01-04 Msd Kk Nouveau derive de benzoxathiine
CA2629018C (fr) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Derive spiro aza-substitue
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
CA2662084A1 (fr) 2006-09-07 2008-03-13 Nycomed Gmbh Polytherapie contre le diabete sucre
WO2008034142A2 (fr) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthèse, procédés d'utilisation et compositions de cycloalkylméthylamines
EP2698157B1 (fr) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
WO2008038692A1 (fr) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. dÉrivÉ de diarylcÉtimine
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008259342B2 (en) 2007-06-04 2014-07-10 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2264026A4 (fr) 2008-03-06 2012-03-28 Msd Kk Dérivé d'alkylaminopyridine
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Ｍｓｄ株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
WO2010013595A1 (fr) 2008-07-30 2010-02-04 萬有製薬株式会社 Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons)
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CA2741672A1 (fr) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
US20100311710A1 (en) * 2008-12-06 2010-12-09 Auspex Pharmaceuticals, Inc. Cyclobutanemethanamine inhibitors of monoamine reuptake
EP2379547A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyridopyrimidine et leurs procédés d'utilisation
WO2010075069A1 (fr) 2008-12-16 2010-07-01 Schering Corporation Dérivés de pyranone bicycliques en tant qu'agonistes des récepteurs nicotiniques
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012003501A2 (fr) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthèse et procédés d'utilisation de dérivés de cycloalkylméthylamine
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (fr) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Nouveaux derives d'azabenzimidazole cyclique utiles en tant qu'agents antidiabetiques
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (fr) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
WO2014151200A2 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions utiles pour le traitement de troubles gastro-intestinaux
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
WO2015068156A1 (fr) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Composés pour le traitement du diabète et des complications pathologiques qui en résultent
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (fr) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Composés de spirochromane antidiabétiques
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
GB2184122B (en) * 1985-12-17 1989-10-18 Boots Co Plc N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment

Also Published As

Publication number Publication date
KR0164435B1 (ko) 1999-01-15
NL300066I2 (nl) 2002-06-03
ZA899058B (en) 1990-08-29
NL300066I1 (nl) 2001-12-01
DE19975039I2 (de) 2000-03-30
DK177690A (da) 1990-09-13
AU4620789A (en) 1990-06-26
IE893690L (en) 1990-05-29
EP0397831B1 (fr) 1993-09-15
DE68909219T2 (de) 1994-01-13
CA2003524C (fr) 1999-10-19
DK175587B1 (da) 2004-12-13
HK1006002A1 (en) 1999-02-05
KR900701261A (ko) 1990-12-01
US5436272A (en) 1995-07-25
IL92406A (en) 1995-07-31
CA2003524A1 (fr) 1990-05-29
JPH06102622B2 (ja) 1994-12-14
PH26677A (en) 1992-09-15
DE68909219D1 (de) 1993-10-21
AU633529B2 (en) 1993-02-04
DK177690D0 (da) 1990-07-26
JPH02503682A (ja) 1990-11-01
IE61928B1 (en) 1994-11-30
WO1990006110A1 (fr) 1990-06-14
EP0397831A1 (fr) 1990-11-22

Similar Documents

Publication Publication Date Title
LU90866I2 (fr) Hydrochlorure de sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorurede sibutramine
LU91131I2 (fr) Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
LU90297I2 (fr) Rivastigmine ses sels et dérivés pharmaceutiquement acceptables en particulier la rivastigmine sous forme d'hydrogénotartrate
GB2188630B (en) Improvements in pharmaceutically acceptable salts
LU91650I2 (fr) Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
NO2005012I2 (no) Triptorelin og farmasoytisk akseptable salter derav
NO2001009I1 (no) Kvetiapin og farmasøytisk akseptable salter derav
NO2006004I2 (no) Erlotinib hydroklorid og farmasøytisk akseptable salter derav
LU91802I2 (fr) Telmisartan, éventuellement sous forme de sels pharmacologiquement acceptables et Amlodipine, éventuellement sous forme de sels pharmacologiquement acceptables, en particulier le bésylate d'Amlodipine
LU90865I2 (fr) Hydrochlorure d sibutramine ses d-riv-s et ses sels pharmaceutiquement acceptables en particulier le monohydrate d'hydrochlorure de sibutramine
LU92681I2 (fr) Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate
NO932127L (no) Imidatderivater og farmasoeytisk nyttige sulfamater med antikonvulserende virkning
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
ITTO940410A0 (it) Articolo per l'introduzione in una apertura
LU90844I2 (fr) es Riamet et ses d-riv-s pharmaceutiquement acceptabl
AU6644986A (en) S-(-)-1-propyl-2', 6' pipecoloxylidide hydrochloride monohydrate and a method for its preparation
NO953673L (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
DK473289D0 (da) 2'-halogenmethyliden-, 2'-ethenyliden- og 2'-ethynyl-adenosin-derivater, deres fremstilling og anvendelse
ZA895271B (en) ((4-piperidyl)methyl)-2,3-dihydro-1h-isoindole and-2,3,4,5-tetrahydro-1h-benzazepine derivatives,their preparation and their application in therapy